11 Mar 2026 | 04:00 PM GMT

Digital Health Business Models: From Evidence to Economic Alignment

Participants:

Laurel Sweeney Market Access & Health Policy Expert Access Strategies LLC
Laurel Sweeney
Market Access & Health Policy Expert Access Strategies LLC
Megan Coder Chief Policy OfficerDIGITAL THERAPEUTICS ALLIANCE, INC
Megan Coder
Chief Policy OfficerDIGITAL THERAPEUTICS ALLIANCE, INC
Bradley Fryer Sales DirectorHLTH
Bradley Fryer
Sales DirectorHLTH
Gezana Rai Events AdministratorHLTH
Gezana Rai
Events AdministratorHLTH
Lauren Gadsby Director, Global Commercial Digital HealthJohnson & Johnson Innovative Medicine
Lauren Gadsby
Director, Global Commercial Digital HealthJohnson & Johnson Innovative Medicine
Louise Nixon Program ManagerHLTH
Louise Nixon
Program ManagerHLTH
Matt Norton VP of Marketing & Commercial DevelopmentS3 Connected Health
Matt Norton
VP of Marketing & Commercial DevelopmentS3 Connected Health
Namita Pande Director, Digital Innovation and StrategyPfizer
Namita Pande
Director, Digital Innovation and StrategyPfizer
Olga LAGUNOVA Director, Global Advanced AnalyticsAbbVie
Olga LAGUNOVA
Director, Global Advanced AnalyticsAbbVie
Rick Bartels President/Founder DTxCC
Rick Bartels
President/Founder DTxCC
Shahid Bobat Director, Global Digital HealthMerck Group
Shahid Bobat
Director, Global Digital HealthMerck Group
Smit Patel AdvisorEconomist Impact
Smit Patel
AdvisorEconomist Impact
Srinivas Nimmagadda CEOACUITYhealth
Srinivas Nimmagadda
CEOACUITYhealth
Stephanie Wakeman AdvisorEquus Growth
Stephanie Wakeman
AdvisorEquus Growth
Stephen Egan DirectorRedicare
Stephen Egan
DirectorRedicare
Stephen Dunne Chief Product & Technology Officer - ManagingKoa Health
Stephen Dunne
Chief Product & Technology Officer - ManagingKoa Health

About this Meeting

The digital health industry has reached a turning point: new RPM and RTM billing codes are live, payers have expanded coverage frameworks, and regulators are signaling long-term support for virtual-first and software-based care models. Yet despite these policy wins, widespread adoption remains uneven. Many organizations are still struggling to translate regulatory green lights into revenue, outcomes, and repeatable operational success.

This discussion examines what it takes to move digital reimbursement from theory to reality. How are innovators converting digital encounters into billable, compliant, and scalable services? What infrastructure — from documentation to audit readiness - is required to satisfy payer scrutiny while maintaining clinical integrity? And where are the bright spots that demonstrate that digital medicine can deliver both health and financial returns?

Participants will explore real-world examples of digital therapeutics and remote patient monitoring programs that have achieved measurable success — and analyze what distinguishes sustainable reimbursement models from pilots that stall.

Join us to discuss:

  • How are innovators translating RPM and RTM codes into scalable cash flow and clinical results?

  • What audit and compliance challenges are emerging as digital reimbursement matures?

  • Which business models best align clinical impact with sustainable payment pathways?